The therapy is being developed to address the underlying cause of Autosomal Dominant Optic Atrophy, a condition that leads to progressive vision loss and currently has no approved treatment options.

The company has named Chisako Mizutani as Country Manager for Japan, bringing more than two decades of experience in clinical research and leadership in contract research organisations.

The trial, spanning multiple centres across the US, is evaluating the performance of RAD 101 in patients with confirmed recurrent brain metastases from a range of solid tumours.

Australian nuclear medicine company Telix Pharmaceuticals has announced a collaboration with Regeneron to develop new targeted cancer treatments.

Argent BioPharma has completed the acquisition of AusCann Group Holdings' interest in CannPal Animal Therapeutics, marking an important step in strengthening its neurological pipeline and expanding its reach into veterinary medicine.

Clarity Pharmaceuticals (ASX:CU6) has taken another step toward the commercialisation of its prostate cancer imaging agent, signing a manufacturing agreement that significantly broadens its production capacity and geographic reach.

Cartherics and Catalent have strengthened their collaboration to accelerate the development and future commercialisation of advanced immune cell therapies.

Entropy Neurodynamics has taken another step forward in its clinical exploration of psychedelic-assisted therapy, announcing that the third patient in its trial of TRP-8803 has completed dosing and achieved what the company describes as a full and controlled psychedelic response.

The companies said feedback from the initial limited launch suggests that this approach is resonating, with more than 80 per cent of caregivers reporting satisfaction, particularly noting the convenience and portability of individual packet dosing. 

The ten-year contract, valued at up to $25.5 million, is designed to ensure that critical treatment resources are immediately available when large-scale burn incidents occur, a scenario where speed and scalability can determine survival outcomes.

Chairman Russell Howard and Chief Executive Marc Voigt acknowledged the disappointment while emphasising that the broader scientific platform remains intact.

Orthocell (ASX:OCC) has joined a cohort of Australian life sciences companies seeking to calm investor nerves over looming US tariff measures, arguing that its business will remain largely untouched even as Washington signals a tougher stance on imported pharmaceuticals.

Mesoblast (ASX:MSB) has received clearance from the US Food and Drug Administration to proceed directly to a registrational trial of its therapy, Ryoncil, in children with Duchenne muscular dystrophy.

The Board of MTPConnect has announced the appointment of Chief Executive Officer Stuart Dignam as a Director, marking a significant milestone as the organisation moves into its second decade of operation.

Telix Pharmaceuticals (ASX:TLX) has delivered robust revenue growth alongside meaningful progress across its therapeutics pipeline in the three months to the end of March 2026.

The company said it has begun reviewing the details of the announcement, with an initial assessment indicating that the majority of its product portfolio in the US market is unlikely to fall within the scope of the tariffs.

The Melbourne-based company had been studying narmafotinib in combination with the widely used but aggressive mFOLFIRINOX regimen in patients with advanced pancreatic cancer.

Vitura Health (ASX:VIT) has appointed experienced healthcare executive Justin James as its new chief executive officer, marking a significant leadership shift as the company positions itself for further expansion in emerging therapies and digital health services.